Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Grapefruit Benefits

Research Into Genetic Neurological Disorders Will Benefit From New Mouse Model
Neurosensory diseases are difficult to model in mice because their symptoms are complex and diverse. The genetic causes identified are often lethal when transferred to a mouse. The lack of animal models slows progress in understanding and treating the diseases. By strategically altering a protein-making molecule, a mouse was made to help understand nervous system diseases that impair feeling and cause paralysis of the arms and legs in humans.
generic viagra online
California HIV/AIDS Advocates To Appear At Hearing On Proposed Budget Cuts
On Friday, HIV/AIDS advocates in California will appear at the state Legislature"s Budget Conference Committee hearing to urge lawmakers to block proposed health-related budget cuts, the Bay Area Reporter reports. According to the Reporter, Gov. Arnold Schwarzenegger"s (R) latest budget proposal includes cutting $67.8 million from state HIV programs and an additional $12.3 million from the AIDS Drug Assistance Program. Anne Donnelly of Project Inform said, "We realize we may have to take cuts to our programs. But let"s make sure they are minimized and that we continue to deliver the essential services to those people living with HIV and those also at risk." Next week HIV/AIDS advocates also plan to convene on the steps of the state Capitol to protest the proposed budget cuts (Bajko, Bay Area Reporter, 6/4).
News of the day
Pacemakers Used To Help Children With Stomach Problems
Physicians at Nationwide Children"s Hospital in Columbus, Ohio are turning to a device typically used in adults with heart problems to help children with severe stomach conditions.
Nutrition

Meda: FDA Approval For Onsolis Anticipated During Summer 2009

Since August 2008, Meda (STO:MEDAA) and BioDelivery Sciences International (BDSI) have worked in close collaboration with the U.S. Food and Drug Administration (FDA) to complete the final requirement of a Risk Evaluation and Mitigation Strategy (REMS) program for Onsolis (fentanyl - treatment of breakthrough cancer pain). Last Friday, FDA"s review Division informed Meda and BDSI that they had reached agreement with the REMS for Onsolis, but that the FDA needed some additional time to complete the final senior level sign off. Meda therefore expects Onsolis to be approved by the FDA during summer, which could enable a fourth quarter 2009 launch, as previously anticipated. MEDA AB (publ) is a leading international specialty pharma company. The company specialises in marketing and pharmaceutical development in late clinical stage. Acquisitions and long-term partnerships drive the company"s strategy. Meda is represented by its own organizations in about 40 countries. Meda"s products are sold in 120 countries worldwide. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange Stockholm. Find out more, visit http://www.meda.se. MEDA AB


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009